Halozyme Therapeutics Files NDA for Enhanze SC

March 28, 2005

Halozyme Therapeutics, a development stage biopharmaceutical company developing and commercializing recombinant human enzymes, has filed a new drug application for Enhanze SC, the first product in Halozyme's Enhanze Technology portfolio.

Enhanze SC is a local formulation of recombinant human hyaluronidase being developed as a "spreading agent" to enhance the drug delivery of local anesthesia, contrast agents, and for subcutaneous fluid replacement (also called hypodermoclysis). Halozyme has received confirmation from the FDA that Enhanze SC will be designated a new chemical entity.